NCT07548645

Brief Summary

This study looks at whether a daily dietary supplement called HOP Box can improve markers of biological aging and overall health in women. HOP Box contains 19 ingredients selected to support cellular health, metabolism, inflammation, and longevity. Thirty-five women between the ages of 35 and 60 will take the supplement twice a day for 90 days. Researchers will measure changes in biological age using an at-home blood test that analyzes DNA methylation patterns, track sleep quality, heart rate, and heart rate variability using an Oura Ring wearable device, and assess participants' self-reported quality of life using a validated health survey (PROMIS-29). There is no placebo or control group in this pilot study - all participants will receive the supplement and serve as their own comparison over time. The goal is to gather early data on whether HOP Box shows promising health effects in women, which would inform the design of a larger, more rigorous trial in the future.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
35

participants targeted

Target at P25-P50 for not_applicable

Timeline
4mo left

Started Mar 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress38%
Mar 2026Aug 2026

Study Start

First participant enrolled

March 1, 2026

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

April 16, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 23, 2026

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 30, 2026

Expected
26 days until next milestone

Study Completion

Last participant's last visit for all outcomes

August 25, 2026

Last Updated

April 23, 2026

Status Verified

April 1, 2026

Enrollment Period

5 months

First QC Date

April 16, 2026

Last Update Submit

April 21, 2026

Conditions

LongevityWomen's Health

Keywords

Women's HealthLongevitySupplementFunctional Health

Outcome Measures

Primary Outcomes (1)

  • TruDiagnostic

    Biologic Age

    Baseline to end-of-study (month 3)

Secondary Outcomes (2)

  • PROMIS-29 v2.0

    Baseline, Month 1, Month 2, and Month 3

  • Oura Ring

    Baseline and End-of-Study (month 3)

Study Arms (1)

Human Optimization Project Arm

EXPERIMENTAL

This arm will receive the active supplement.

Dietary Supplement: Human Optimization Project

Interventions

Human Optimization ProjectDIETARY_SUPPLEMENT

There is only 1 intervention in this single-arm study.

Also known as: HOP Box
Human Optimization Project Arm

Eligibility Criteria

Age35 Years - 60 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsEligible participants must be biological females who self-identify as women, aged 35 to 60 years. The intervention targets sex-specific biological pathways relevant to female health and aging
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Women aged 35 to 60 years, English-speaking, and residing in the United States
  • Must own an Oura Ring with an active membership and a minimum of 30 days of baseline data
  • Willingness to comply with all study procedures, assessments, lifestyle considerations, and follow-ups for the study duration
  • Medically stable with no significant health changes in the past three months

You may not qualify if:

  • Current use of GLP-1 receptor agonists (e.g., semaglutide, liraglutide), SGLT2 inhibitors (e.g., canagliflozin, dapagliflozin, empagliflozin), insulin, metformin, thiazolidinediones, acarbose, alpha-glucosidase inhibitors, or any investigational drug or supplement within the past 30 days
  • Current use of NAD+ precursors (nicotinamide riboside, NMN, niacin, NAD+), supplements containing active ingredients already in the HOP Box formulation, high-dose vitamin B12, berberine, alpha-lipoic acid, or other glucose-lowering supplements
  • Confirmed diagnosis of Type 1 or Type 2 diabetes, known liver disease (hepatitis, cirrhosis, NAFLD), kidney disease (including CKD or renal impairment), active or recent cancer (within past 5 years, excluding non-melanoma skin cancers), or severe psychiatric/mood disorders (bipolar disorder, schizophrenia, or major depressive disorder requiring hospitalization or intensive psychiatric intervention)
  • Known allergy, hypersensitivity, or intolerance to any active or inactive ingredient in the intervention
  • Participation in any other clinical trial, wellness intervention, or investigational product study within the 30 days prior to enrollment
  • Currently pregnant, breastfeeding, or planning to become pregnant within the next 12 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Reputable Health

Wilmington, Delaware, 19808, United States

Location

Related Links

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of Clinical Research

Study Record Dates

First Submitted

April 16, 2026

First Posted

April 23, 2026

Study Start

March 1, 2026

Primary Completion (Estimated)

July 30, 2026

Study Completion (Estimated)

August 25, 2026

Last Updated

April 23, 2026

Record last verified: 2026-04

Locations

US(1)